KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organon (OGN) EBT (2020 - 2025)

Organon has reported EBT over the past 6 years, most recently at -$148.0 million for Q4 2025.

  • Quarterly results put EBT at -$148.0 million for Q4 2025, down 214.73% from a year ago — trailing twelve months through Dec 2025 was $425.0 million (down 47.34% YoY), and the annual figure for FY2025 was $425.0 million, down 47.34%.
  • EBT for Q4 2025 was -$148.0 million at Organon, down from $243.0 million in the prior quarter.
  • Over the last five years, EBT for OGN hit a ceiling of $467.0 million in Q1 2021 and a floor of -$1.5 billion in Q4 2022.
  • Median EBT over the past 5 years was $235.5 million (2021), compared with a mean of $149.2 million.
  • Biggest five-year swings in EBT: tumbled 719.49% in 2022 and later soared 158.75% in 2024.
  • Organon's EBT stood at $236.0 million in 2021, then plummeted by 719.49% to -$1.5 billion in 2022, then surged by 107.11% to $104.0 million in 2023, then rose by 24.04% to $129.0 million in 2024, then crashed by 214.73% to -$148.0 million in 2025.
  • The last three reported values for EBT were -$148.0 million (Q4 2025), $243.0 million (Q3 2025), and $229.0 million (Q2 2025) per Business Quant data.